Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

A placebo-controlled randomized trial of D-cycloserine augmentation of cue exposure therapy for smoking cessation.

Otto MW, Pachas GN, Cather C, Hoeppner SS, Moshier SJ, Hearon BA, Ward HB, Laffer AB, Smits JAJ, Evins AE.

Cogn Behav Ther. 2019 Jan;48(1):65-76. doi: 10.1080/16506073.2018.1476908. Epub 2018 Aug 16.

PMID:
30111253
2.

Phase IIb Trial of an α7 Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence.

Schuster RM, Pachas GN, Stoeckel L, Cather C, Nadal M, Mischoulon D, Schoenfeld DA, Zhang H, Ulysse C, Dodds EB, Sobolewski S, Hudziak V, Hanly A, Fava M, Evins AE.

J Clin Psychopharmacol. 2018 Aug;38(4):307-316. doi: 10.1097/JCP.0000000000000919.

PMID:
29912798
3.

Anterior insula activation during inhibition to smoking cues is associated with ability to maintain tobacco abstinence.

Gilman JM, Radoman M, Schuster RM, Pachas G, Azzouz N, Fava M, Evins AE.

Addict Behav Rep. 2018 Jan 9;7:40-46. doi: 10.1016/j.abrep.2018.01.002. eCollection 2018 Jun.

4.

Using Functional Near-Infrared Spectroscopy to Measure Effects of Delta 9-Tetrahydrocannabinol on Prefrontal Activity and Working Memory in Cannabis Users.

Keles HO, Radoman M, Pachas GN, Evins AE, Gilman JM.

Front Hum Neurosci. 2017 Oct 10;11:488. doi: 10.3389/fnhum.2017.00488. eCollection 2017.

5.

Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations.

Cather C, Pachas GN, Cieslak KM, Evins AE.

CNS Drugs. 2017 Jun;31(6):471-481. doi: 10.1007/s40263-017-0438-8. Review.

6.

Improved Depressive Symptoms in Adults with Schizophrenia During a Smoking Cessation Attempt with Varenicline and Behavioral Therapy.

Cather C, Hoeppner S, Pachas G, Pratt S, Achtyes E, Cieslak KM, Evins AE.

J Dual Diagn. 2017 Jul-Sep;13(3):168-178. doi: 10.1080/15504263.2017.1319585. Epub 2017 Apr 17.

PMID:
28414583
7.

Predictors of tobacco abstinence in outpatient smokers with schizophrenia or bipolar disorder treated with varenicline and cognitive behavioral smoking cessation therapy.

Schuster RM, Cather C, Pachas GN, Zhang H, Cieslak KM, Hoeppner SS, Schoenfeld D, Evins AE.

Addict Behav. 2017 Aug;71:89-95. doi: 10.1016/j.addbeh.2017.02.028. Epub 2017 Feb 24.

PMID:
28285208
8.

A two-site, two-arm, 34-week, double-blind, parallel-group, randomized controlled trial of reduced nicotine cigarettes in smokers with mood and/or anxiety disorders: trial design and protocol.

Allen SI, Foulds J, Pachas GN, Veldheer S, Cather C, Azzouz N, Hrabovsky S, Hameed A, Yingst J, Hammett E, Modesto J, Krebs NM, Zhu J, Liao J, Muscat JE, Richie J, Evins AE.

BMC Public Health. 2017 Jan 19;17(1):100. doi: 10.1186/s12889-016-3946-4.

9.

Maintenance pharmacotherapy normalizes the relapse curve in recently abstinent tobacco smokers with schizophrenia and bipolar disorder.

Evins AE, Hoeppner SS, Schoenfeld DA, Hoeppner BB, Cather C, Pachas GN, Cieslak KM, Maravic MC.

Schizophr Res. 2017 May;183:124-129. doi: 10.1016/j.schres.2016.11.018. Epub 2016 Dec 9.

10.

Weight gain and 10-year cardiovascular risk with sustained tobacco abstinence in smokers with serious mental illness: a subgroup analysis of a randomized trial.

Thorndike AN, Achtyes ED, Cather C, Pratt S, Pachas GN, Hoeppner SS, Evins AE.

J Clin Psychiatry. 2016 Mar;77(3):e320-6. doi: 10.4088/JCP.15m10074.

PMID:
27046320
11.

Erratum to: Single dose propranolol does not affect physiologic or emotional reactivity to smoking cues.

Pachas GN, Gilman J, Orr SP, Hoeppner B, Carlini SV, Grasser EB, Loebl T, Nino J, Pitman RK, Evins AE.

Psychopharmacology (Berl). 2015 Jun;232(11):2029. doi: 10.1007/s00213-015-3930-1. No abstract available.

PMID:
25877745
12.

Single dose propranolol does not affect physiologic or emotional reactivity to smoking cues.

Pachas GN, Gilman J, Orr SP, Hoeppner B, Carlini SV, Grasser EB, Loebl T, Nino J, Pitman RK, Evins AE.

Psychopharmacology (Berl). 2015 May;232(9):1619-28. doi: 10.1007/s00213-014-3797-6. Epub 2014 Nov 22. Erratum in: Psychopharmacology (Berl). 2015 Jun;232(11):2029. Grasser, Elisabeth B [added].

13.

Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.

Evins AE, Cather C, Pratt SA, Pachas GN, Hoeppner SS, Goff DC, Achtyes ED, Ayer D, Schoenfeld DA.

JAMA. 2014 Jan 8;311(2):145-54. doi: 10.1001/jama.2013.285113.

14.

Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study.

Barake M, Evins AE, Stoeckel L, Pachas GN, Nachtigall LB, Miller KK, Biller BM, Tritos NA, Klibanski A.

Pituitary. 2014 Apr;17(2):150-6. doi: 10.1007/s11102-013-0480-6.

15.

Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial.

Pachas GN, Cather C, Pratt SA, Hoeppner B, Nino J, Carlini SV, Achtyes ED, Lando H, Mueser KT, Rigotti NA, Goff DC, Evins AE.

J Dual Diagn. 2012;8(2):117-125. Epub 2012 May 11.

16.

A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females.

Evins AE, Pachas G, Mischoulon D, Urbanoski K, Carlini S, Sousa J, Bentley K, Rigotti NA, Nino-Gomez J, Loebl T, Janes AC, Kaufman MJ, Fava M.

J Clin Psychopharmacol. 2011 Oct;31(5):597-602. doi: 10.1097/JCP.0b013e31822bb390.

17.

Anterior cingulate proton spectroscopy glutamate levels differ as a function of smoking cessation outcome.

Mashhoon Y, Janes AC, Jensen JE, Prescot AP, Pachas G, Renshaw PF, Fava M, Evins AE, Kaufman MJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1709-13. doi: 10.1016/j.pnpbp.2011.05.006. Epub 2011 May 15.

18.

Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence.

Janes AC, Pizzagalli DA, Richardt S, deB Frederick B, Chuzi S, Pachas G, Culhane MA, Holmes AJ, Fava M, Evins AE, Kaufman MJ.

Biol Psychiatry. 2010 Apr 15;67(8):722-9. doi: 10.1016/j.biopsych.2009.12.034. Epub 2010 Feb 20. Erratum in: Biol Psychiatry. 2010 May 15;67(10):1002.

19.

High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.

Dyer MA, Freudenreich O, Culhane MA, Pachas GN, Deckersbach T, Murphy E, Goff DC, Evins AE.

Schizophr Res. 2008 Jul;102(1-3):88-95. doi: 10.1016/j.schres.2007.12.491. Epub 2008 Mar 5.

20.

A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men.

Loebl T, Angarita GA, Pachas GN, Huang KL, Lee SH, Nino J, Logvinenko T, Culhane MA, Evins AE.

J Clin Psychiatry. 2008 Mar;69(3):480-6.

PMID:
18294021

Supplemental Content

Loading ...
Support Center